[Anticholinergics and their cardiovascular effects--between fear and reality].
Mihălţan
Florin
F
Institutul de Pneumologie "Marius Nasta", Bucureşti. mihaltan@starnets.ro
Ulmeanu
Ruxandra
R
D000280:Administration, Inhalation; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000401:mortality; D018680:Cholinergic Antagonists / Q000008:administration & dosage / Q000009:adverse effects*; D019317:Evidence-Based Medicine; D006333:Heart Failure / Q000139:chemically induced; D006801:Humans; D009241:Ipratropium / Q000008:administration & dosage / Q000009:adverse effects*; D017202:Myocardial Ischemia / Q000139:chemically induced; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000401:mortality; D012307:Risk Factors; D012602:Scopolamine Derivatives / Q000008:administration & dosage / Q000009:adverse effects*; D012907:Smoking / Q000009:adverse effects; D016019:Survival Analysis; D000069447:Tiotropium Bromide
D018680:Cholinergic Antagonists; D012602:Scopolamine Derivatives; D009241:Ipratropium; D000069447:Tiotropium Bromide